APASL 2017 - Triple DAA combo containing ritonavir effective, safe for HCV GT1b in Asians

MIMS Hepatology

Triple DAA combo containing ritonavir effective, safe for HCV GT1b in Asians

13 hours ago, Pearl Toh

A combination of the direct-acting antiviral agents (DAAs) ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) and dasabuvir (DSV) resulted in sustained virologic response at post-treatment week 12 (SVR12) in almost all Asian adult patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection without cirrhosis, according to the ONYX-I* study presented at the recent Asian Pacific Association for the Study of the Liver Annual Meeting (APASL 2017) held in Shanghai, China.

Continue reading...

Conference Coverage
Slides @ NATAP
Feb 21
ONYX-II: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Coadministered with Ribavirin in Asian Adults with Genotype 1b Chronic Hepatitis C Virus Infection and Compensated Cirrhosis

Of Interest
AASLD
The Liver Meeting
Boston MA
November 2016
ONYX-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Asian Adults With Genotype 1b Chronic Hepatitis C Virus Infection - A Randomized, Double-Blind, Placebo-Controlled Study - (11/17/16)

ONYX-II: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Coadministered With Ribavirin in Asian Adults With Genotype 1b Chronic Hepatitis C Virus Infection and Compensated Cirrhosis - (11/17/16)

July 25, 2016

FDA approves a New Drug Application (NDA) for VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir)

APASL-Cocrystal Pharma to Present Data on Pan-genotypic NS5B Non-nucleoside Inhibitor CC-31244 for the Treatment of Hepatitis C Virus Infection

Cocrystal Pharma to Present Clinical Data on its Potent Pan-genotypic NS5B Non-nucleoside Inhibitor CC-31244 at the Asian Pacific Association for the Study of the Liver (APASL) Annual Meeting
Posted on: 16 Feb 17

BOTHELL, Wash. and ATLANTA, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (OTCQB:COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today that it has been selected to give an oral presentation on Saturday, February 18, 2017, 3:45 PM Shanghai time (2:45 AM ET) entitled, “Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Antiviral Activity of CC-31244, a Pan-Genotypic, Potent Non-Nucleoside NS5B Polymerase Inhibitor for the Treatment of Hepatitis C Virus Infection” at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) held in Shanghai, February 15-19, 2017.

The interim results from the ongoing, randomized, double-blind, Phase 1a/1b study of CC-31244, a pan-genotypic, potent NS5B non-nucleoside inhibitor (NNI) will be presented by Sam Lee, Ph.D., President and co-inventor of the drug. CC-31244 monotherapy produced up to a 3 log drop in viral load with a slow viral rebound post treatment following a 7 day treatment suggesting that CC-31244 could be an important component in an all oral, shorter HCV combination therapy.

Cocrystal Pharma's interim Chief Executive Officer, Dr. Gary Wilcox said, "We are pleased to be given the opportunity to present the interim data at APASL. The interim results show that CC-31244 had a substantial and durable antiviral effect with a favorable safety and tolerability profile in both healthy volunteers and HCV GT1 infected individuals.”

An archived edition of the presentation will be available on the Cocrystal website, www.cocrystalpharma.com, shortly after the event.

About CC-31244
CC-31244 is an investigational, oral, potent, pan-genotypic NNI with high barrier to drug resistance designed and developed using the Company's proprietary structure-based drug discovery technology. The molecule interacts with the NS5B RNA polymerase of all major HCV genotypes.

More: http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=206045#.WKYUwIWcGmQ#ixzz4YsvAd0wa